LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

Kodu・Aktsiate loetelu・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Suletud

1.27

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.24

Max

1.28

Põhinäitajad
By Trading Economics
Sissetulek	17M -26M
Töötajad	171
EBITDA	19M -23M

Soovitused
By TipRanks
Soovitused	Müü
12 kuu keskmine prognoos	+53.85% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. märts 2026

Turustatistika
By TradingEconomics
Turukapital	-27M 76M
Eelmine avamishind	1.27
Eelmine sulgemishind	1.27

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.43 / 1.6 Toetus ja vastupanu

Pliant Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. märts 2026, 23:41 UTC

Market Talk

Uudisväärsed sündmused

Nikkei May Decline on Concerns About Energy Prices -- Market Talk

2. märts 2026, 23:37 UTC

Market Talk

Uudisväärsed sündmused

Gold Edges Higher Amid Middle East Conflict -- Market Talk

2. märts 2026, 23:26 UTC

Uudisväärsed sündmused

How the Iran Conflict Could Pressure Consumer Staples Companies -- Barrons.com

2. märts 2026, 22:41 UTC

Market Talk

Australian Reits Wait on Recovery in Trading Multiples -- Market Talk

2. märts 2026, 22:32 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2. märts 2026, 22:32 UTC

Market Talk

RBA Cautious About Potential for Energy Supply Shocks -- Market Talk

2. märts 2026, 22:21 UTC

Market Talk

Port of Tauranga's Upgraded Profit View Still Looks Conservative -- Market Talk

2. märts 2026, 22:11 UTC

Market Talk

Global Equities Roundup: Market Talk

2. märts 2026, 22:11 UTC

Market Talk

Don't Lose Sight of Bigger Picture With Summerset -- Market Talk

2. märts 2026, 22:10 UTC

Omandamised, ülevõtmised, äriostud

IAC Is Near Deal to Sell Care.com to Private-Equity Firm -- WSJ

2. märts 2026, 22:06 UTC

Market Talk

Channel Infrastructure's Dividend Positively Surprises -- Market Talk

2. märts 2026, 22:00 UTC

Market Talk

Tulu

Global Forex and Fixed Income Roundup: Market Talk

2. märts 2026, 22:00 UTC

Market Talk

Tulu

Fashion Retailer Hallenstein Glasson Still a Smart Buy -- Market Talk

2. märts 2026, 21:50 UTC

Market Talk

Uudisväärsed sündmused

Energy & Utilities Roundup: Market Talk

2. märts 2026, 21:50 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

2. märts 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

2. märts 2026, 21:35 UTC

Omandamised, ülevõtmised, äriostud

AT&T Expects Net Debt-To-Adjusted Ebitda Ratio Will Rise to About 3.2x Following Deal With EchoStar and Decline to About 3x by End of 2026

2. märts 2026, 21:34 UTC

Omandamised, ülevõtmised, äriostud

AT&T Remains on Track to Achieve Its 2026 and Multi-Yr Fincl Guidance

2. märts 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2. märts 2026, 21:17 UTC

Uudisväärsed sündmused

Bank, Brokerage Stocks Recover Lost Ground After Last Week's Selloff -- Despite Iran Conflict -- Barrons.com

2. märts 2026, 20:44 UTC

Tulu

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2. märts 2026, 20:43 UTC

Market Talk

Uudisväärsed sündmused

Treasury Yields Fall, Dollar Strengthens After Attack on Iran -- Market Talk

2. märts 2026, 20:28 UTC

Tulu

Strategy Stock Rises. The World's Largest Bitcoin Holder Doubles Down on Its Crypto Bet. -- Barrons.com

2. märts 2026, 20:25 UTC

Market Talk

Uudisväärsed sündmused

U.S. Natural Gas Futures Post Moderate Gains -- Market Talk

2. märts 2026, 20:24 UTC

Tulu

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2. märts 2026, 20:14 UTC

Omandamised, ülevõtmised, äriostud

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2. märts 2026, 20:12 UTC

Uudisväärsed sündmused

Palantir Rises on Mideast Conflict. Why It's Moving Like a Defense Stock. -- Barrons.com

2. märts 2026, 20:08 UTC

Market Talk

Uudisväärsed sündmused

Global Forex and Fixed Income Roundup: Market Talk

2. märts 2026, 20:08 UTC

Market Talk

Uudisväärsed sündmused

Higher Oil Prices Could Boost Capex in Canada Energy Patch -- Market Talk

2. märts 2026, 20:05 UTC

Market Talk

Uudisväärsed sündmused

Oil Rises On U.S.-Middle East Conflict, But Settles Off Highs -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Pliant Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

53.85% tõus

12 kuu keskmine prognoos

Keskmine 2 USD 53.85%

Kõrge 2 USD

Madal 2 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Pliant Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Müü

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi Pliant Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.43 / 1.6Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.